Vanguard Group Inc. Has $114.71 Million Stock Holdings in STAAR Surgical Company $STAA

Vanguard Group Inc. reduced its stake in STAAR Surgical Company (NASDAQ:STAA) by 2.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,269,123 shares of the medical instruments supplier’s stock after selling 121,644 shares during the quarter. Vanguard Group Inc. owned about 8.65% of STAAR Surgical worth $114,711,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in STAA. CWM LLC grew its holdings in STAAR Surgical by 74.1% in the 2nd quarter. CWM LLC now owns 1,563 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 665 shares in the last quarter. GAMMA Investing LLC raised its position in shares of STAAR Surgical by 61.4% in the third quarter. GAMMA Investing LLC now owns 1,856 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 706 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in STAAR Surgical by 691.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,607 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 3,151 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of STAAR Surgical by 375.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 4,673 shares during the period. Finally, Wolverine Asset Management LLC bought a new position in shares of STAAR Surgical in the third quarter worth $199,000. Institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on STAA. Morgan Stanley began coverage on shares of STAAR Surgical in a research report on Friday, January 16th. They set an “underweight” rating and a $13.00 price objective for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of STAAR Surgical in a research report on Thursday, January 22nd. Wells Fargo & Company increased their target price on shares of STAAR Surgical from $28.00 to $30.75 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. BTIG Research reaffirmed a “neutral” rating on shares of STAAR Surgical in a report on Tuesday, January 6th. Finally, Wedbush began coverage on shares of STAAR Surgical in a research note on Tuesday, February 3rd. They issued a “neutral” rating and a $26.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $20.78.

Insider Buying and Selling

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 27,485 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were bought at an average cost of $22.05 per share, with a total value of $606,044.25. Following the purchase, the insider directly owned 15,453,629 shares of the company’s stock, valued at $340,752,519.45. This trade represents a 0.18% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired a total of 434,138 shares of company stock worth $9,424,176 over the last quarter. Corporate insiders own 0.59% of the company’s stock.

STAAR Surgical News Summary

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Management said it is targeting a return to profitability in 2026 after a volatile 2025, giving investors a recovery path to model. STAAR Surgical Eyes 2026 Profit
• Positive Sentiment: Geographic strength — especially strong sales growth in China — helped total revenue rise ~18% year‑over‑year, signaling demand resilience for EVO ICL products. Q4 Highlights: China Growth
• Positive Sentiment: Gross margins expanded as cost of sales declined and the company finished the quarter with a solid cash balance (~$153M), which supports the recovery plan. Q4 Financial Details
• Neutral Sentiment: Analysts remain mixed: Needham maintained a Hold (neutral) view, reflecting short‑term revenue headwinds but belief in a 2026 recovery. Needham Hold Rating
• Neutral Sentiment: Company issued a shareholder letter and held an earnings call/transcript that provide more detail on near‑term actions and leadership transition — useful for modeling timing of the turnaround. Shareholder Letter Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations: revenue of $57.8M fell well short of Street estimates and the company reported a net loss and operating loss, with diluted EPS near -$0.37 — this is the primary reason for the sell‑reaction. Q4 Results & Miss
• Negative Sentiment: Stifel cut its price target to $18 and moved to a Hold after the “noisy” Q4 print, signaling reduced near‑term upside and increased analyst caution. Stifel PT Cut
• Negative Sentiment: Despite y/y revenue growth, operating loss widened and EPS missed consensus, creating near‑term execution risk until the company demonstrates consistent top‑line recovery. Earnings Miss Coverage

STAAR Surgical Stock Up 1.6%

Shares of STAAR Surgical stock opened at $19.22 on Thursday. The stock has a market cap of $956.00 million, a price-to-earnings ratio of -11.79 and a beta of 1.05. STAAR Surgical Company has a twelve month low of $14.69 and a twelve month high of $30.81. The company’s fifty day moving average is $19.88 and its 200 day moving average is $24.15.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.51). STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.01%. The company had revenue of $57.80 million during the quarter, compared to the consensus estimate of $75.54 million. The company’s revenue was up 18.0% on a year-over-year basis. As a group, equities analysts anticipate that STAAR Surgical Company will post -1.14 earnings per share for the current fiscal year.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.